AMENDMENTS TO THE CLAIMS

The following replaces all prior versions, and listing of claims, made in this application.

1-18 (Canceled)

19. (Currently Amended) A method comprising:

a) administering an MRI agent having the formula:

 Y_1 and Y_2 are independently amino acid moieties; n and m are each independently an integer from 0 to 5 X_1 is an independent linker; and

b) producing a magnetic resonance image of a cell, tissue, or patient.

salts thereof:

20. (Currently Amended) A method comprising:

a) administering an activatable MRI agent having the formula:

N
$$X_1$$
 MMP peptide $(X_2)_p$ M O O

wherein

M is a paramagnetic metal ion selected from the group consisting of Gd(III), Fe(III), Mn(II),

Y(III), Cr(III), Eu(III), and Dy(III);

X. and X. are each independent linkers;

74 and 74 are each marpenant minera,

X1 is an aryl group or an alkyl group;

X_2 is an aryl group, an alkyl group, a carbohydrate group, a nucleic acid group, or a lipid group;

MMP is a matrix metalloproteinase (MMP) active peptide;

p is an integer from 0 to 1; and

salts thereof:

- b) contacting said MRI agent under conditions wherein said MMP active peptide is cleaved by interacts with a MMP such that the T₁ of the said MRI agent is decreased; and,
- producing a magnetic resonance image of a cell, tissue, or patient.
- 21. (Previously Presented) A method according to claim 19, wherein said M is Gd(III).
- (Previously Presented) A method according to claim 20, wherein said M is Gd(III).
- (Previously Presented) A method according to claim 19, wherein X₁ is selected from the group
 consisting of an arvl or alkyl group.

1-SF/7641500·1

- (Canceled) A method according to claim 20, wherein X₁ is selected from the group consisting of an aryl or alkyl group.
- (Canceled) A method according to claim 20, wherein X2 is selected from the group consisting of
 an aryl group, an alkyl group, a carbohydrate group, a nucleic acid group, a lipid group, and combinations
 thereof.
- 26. (Previously Presented) A method according to claim 19, wherein X₁ is -(CH₂CO)-, Y₁ is -Pro-Met- when n = 2. and Y₂ is --Tro-Met-Arg when m = 1 (SEO ID NO: 4).
- 27. (Previously Presented) A method according to claim 19, wherein X₁ is -(CH₂CO)-, Y₁ is -Metwhen n = 1, and Y₂ is -Trp-Met-Arg when m = 3 (SEQ ID NO:2).
- 28. (Previously Presented) A method according to claim 19, wherein X_1 is –(CH₂CO)-, n = 0, and Y_2 is –Trp-Met-Arg when m = 3 (SEQ ID NO:3).
- 29. (Previously Presented) A method according to claim 20, wherein said MMP is MMP 7.
- (Previously Presented) A method according to claim 20, wherein X₁ is -(CH₂CO)-, said MMP peptide comprises Leu-Met-Trp-Arg, and p = 0 (SEQ ID NO:20).
- 31. (Previously Presented) A method comprising:
 - a) administering an MRI agent having the formula:

wherein

M is a paramagnetic metal ion selected from the group consisting of Gd(III), Fe(III), Mn(II), Y(III), Cr(III), Eu(III), and Dy(III);

X₁ and X₂ are each independent linkers;

MMP is a matrix metalloproteinase (MMP) active peptide; and salts thereof:

- b) contacting said MRI agent under conditions wherein said MMP active peptide interacts
 with a MMP such that the T₁ of the said MRI agent is decreased; and,
 - producing a magnetic resonance image of a cell, tissue, or patient.
- 33, (Previously Presented) A method according to claim 31, wherein said M is Gd(III).
- e (Previously Presented) A method according to claim 31, wherein X_1 and X_2 are independently es 4 cted from the group consisting of p-aminobenzyl or substituted p-aminobenzyl.
- (Previously Presented) A method according to claim 31, wherein said MMP peptide is Pro-Met-A a-Leu-Trp-Met-Arg (SEQ ID NO: 4).
- 35. (Previously Presented) A method according to claim 31, wherein said MMP is MMP 7.

36. (Previously Presented) A method according to claim 31, wherein said MRI agent has the

formula: